AI Article Synopsis
- The study aimed to evaluate the effectiveness of Ingavirin against different strains of pandemic influenza viruses, including A(H1N1/09)v, A(H5N1), and A(H3N2).
- The research involved experimenting with MDCK cell cultures and infected mice to observe the viruses' activity and measure titers in lung tissues after treatment with Ingavirin, Tamiflu, or Remantadin.
- Results showed that Ingavirin significantly reduced the activity of A(H1N1/09)v and A(H3N2) in mice, indicating its effectiveness, while these strains were found to be resistant to Remantadin.
Article Abstract
Aim: To study efficacy of Ingavirin in vitro and in vivo against strains of pandemic influenza virus A(H1N1/09)v and influenza virus A(H5N1) and A(H3N2).
Materials And Methods: Changes in hemagglutinating and cytopathic activity of influenza virus strains A(H1N1/09)v, A(H5N1) and A(H3N2) during their incubation in the presence of Ingavirin or Remantadin on MDCK cell culture were studied. In mice infected by influenza strains A(H1N1/09)v and A(H3N2) and orally treated with Ingavirin, Tamiflu or Remantadin virus titers in lungs were measured.
Results: There was decrease in hemagglutinating and cytopathic activity of influenza virus strains after incubation with Ingavirin in vitro. Ingavirin effectively inhibited reproduction of influenza virus strains A(H1N1/09)v and A(H3N2) in lungs of infected mice. Titers of these strains in lung homogenates decreased when Ingavirin was orally administered to infected mice.
Conclusion: Strains of influenza virus A(H1N1/09)v were susceptible to Ingavirin and Tamiflu but resistant to Remantadin. Reference strains of A(H5N1) and A(H3N2) were susceptible to Ingavirin, Tamiflu and Remantadin.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!